Efficacy and Safety of Nasal Administration of “Na-no-L-DOPA” Based on PLGA Nanoparticles

I.G. Kondrasheva, T.A. Antipova, G.G. Barsegyan, P.Ye. Gambaryan, A.A. Guseva, A.A. Kamensky

Moscow State University Moscow, Russia.
Research Center of Molecular Diagnostics & Therapy Moscow, Russia.

DOI: 10.4236/eng.2012.410B007                

Abstract

Inclusion of L-DOPA, the standard Parkinson’s disease medication, into polymeric particles (PLGA) results in optimization the drug metabolism and increasing its bioavailability, significantly increases of physical endurance, better coordination and lower anxiety in Wistar rats, when chronically administered nasally.

Keywords

Nanopaticls; L-DOPA; Nasal Administration; Parkinson’s Disease

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	A. Pires, A. Fortuna, G. Alves, A. Falcao Intranasal Drug Delivery: How, Why and What for? J Pharm Pharmaceut Sci, 2009, vol. 12(3) pp. 288 - 311
[2]	Graff CL, Pollack GM. Nasal drug administration: Potential for targeted central nervous system delivery. J Pharm Sci, 2005, vol. 94, pp. 1187–1195.
[3]	Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci, 2000, vol. 11, pp 1–18.
[4]	Illum L. Is nose-to-brain transport of drugs in man a reality. J Pharm Pharmacol, 2004, vol. 56, pp. 3–17.
[5]	Dahlin M, Jansson B, Bjork E.. Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci, 2001, vol. 14. pp. 75–80.
[6]	M.Fazil, Shadab, S. Baboota, JK Sahni, J Ali Nanotherapeutics for Alzheimer's disease (AD): past, present and future, Journal of Drug Targeting, 2012, vol. 20 (2), pp. 97-113.
[7]	Henry, R.J., Ruano N, Casto D, Wolf RH, A pharmacokinetic study of midazolam in dogs: nasal drop vs. atomizer administration. Pediatr Dent, 1998, vol. 20(5), pp. 321-326.
[8]	Sakane, T., Akizuki M, Yoshida M, Yamashita S, Nadai T, Hashida M, Sezaki H. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J Pharm Pharmacol, 1991, vol. 43(6), pp. 449-451.
[9]	Banks, W.A., M.J. During, and M.L. Niehoff Brain uptake of the glucagon-like peptide-1 antagonist exendin (9-39) after intranasal administration. J Pharmacol Exp Ther, 2004, vol. 309(2), pp. 469-475.
[10]	Westin, Bostrom E, Grasjo J, Hammarlund-Udenaes M, Bjork E. Direct nose-to-brain transfer of morphine after nasal administration to rats. Pharm Res, 2006, vol. 23(3), pp. 565-572.
[11]	Kreuter J. Nanoparticulate system for brain delivery of drags. Adv Drug Deliv Rev, 2001, vol. 47, pp. 65-81.
[12]	Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. Characterization of nanoparticles for therapeutics. Nanomedicine (Lond). 2007, Dec, vol. 2(6), pp. 789-803